中华临床医师杂志(电子版)
中華臨床醫師雜誌(電子版)
중화림상의사잡지(전자판)
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
5期
1961-1964
,共4页
癌,非小细胞肺%药物疗法,联合%治疗结果
癌,非小細胞肺%藥物療法,聯閤%治療結果
암,비소세포폐%약물요법,연합%치료결과
Carcinoma,non-small-cell lung%Drug therapy,combination%Treatment outcome
目的比较DP、NP、GP、EP化疗方案治疗非小细胞肺癌的临床疗效与安全性差异,为非小细胞肺癌方案的优化提供借鉴。方法回顾分析208例符合入组标准的晚期非小细胞肺癌患者的临床资料,按随机抽查的原则分为4组,分别为DP组58例、NP组56例、GP组50例、EP组44例,DP组给予多西他赛+顺铂治疗,NP组给予长春瑞滨+顺铂治疗,GP组给予吉西他滨+顺铂治疗,EP组给予依托泊苷+顺铂治疗,比较不同治疗方案的WHO实体瘤近期疗效,记录试验过程出现的不良反应进行比较,分析生存情况。结果(1)DP组、NP组、GP组、EP组的总有效率分别为56%、54%、48%、36%,DP组、NP组之间总有效率差异无统计学意义(χ2=1.103, P>0.05), DP组、GP组之间总有效率差异无统计学意义(χ2=1.162, P>0.05),NP组、GP组之间总有效率差异无统计学意义(χ2=0.142,P>0.05),DP组、NP组、GP组均明显高于EP组,差异具有统计学意义(χ2=25.184、19.636、19.821,均P<0.05);(2) DP组、NP组、GP组、EP组1年、2年生存率分别为46.6%和27.6%,42.8%和25%,44%和26%,22.7%和9.1%, DP组、NP组之间1年、2年生存率差异无统计学意义(χ2=0.157、0.108,P>0.05),DP组、GP组之间1年、2年生存率差异无统计学意义,(χ2=0.071、0.219, P>0.05);NP组、GP组之间1年、2年生存率差异没有统计学意义(χ2=0.014、0.022,P>0.05);DP组、NP组、GP组的1年、2年生存率均明显高于EP 组,差异具有统计学意义(χ2=6.143、4.493、4.717和4.643、4.225、4.517,均P<0.05);(3)DP组、NP组、GP组、EP组白细胞减少、血小板减少、贫血、神经毒性、恶心呕吐、肝功能损害、肾功能损害的发生率差异无统计学意义(均P>0.05)。结论 DP、NP、GP治疗中晚期非小细胞肺癌临床疗效确切,有效率、生存率相近,且患者能耐受性均较好,均可作为一线治疗方案,应根据患者特点,个体化选择三个化疗方案。
目的比較DP、NP、GP、EP化療方案治療非小細胞肺癌的臨床療效與安全性差異,為非小細胞肺癌方案的優化提供藉鑒。方法迴顧分析208例符閤入組標準的晚期非小細胞肺癌患者的臨床資料,按隨機抽查的原則分為4組,分彆為DP組58例、NP組56例、GP組50例、EP組44例,DP組給予多西他賽+順鉑治療,NP組給予長春瑞濱+順鉑治療,GP組給予吉西他濱+順鉑治療,EP組給予依託泊苷+順鉑治療,比較不同治療方案的WHO實體瘤近期療效,記錄試驗過程齣現的不良反應進行比較,分析生存情況。結果(1)DP組、NP組、GP組、EP組的總有效率分彆為56%、54%、48%、36%,DP組、NP組之間總有效率差異無統計學意義(χ2=1.103, P>0.05), DP組、GP組之間總有效率差異無統計學意義(χ2=1.162, P>0.05),NP組、GP組之間總有效率差異無統計學意義(χ2=0.142,P>0.05),DP組、NP組、GP組均明顯高于EP組,差異具有統計學意義(χ2=25.184、19.636、19.821,均P<0.05);(2) DP組、NP組、GP組、EP組1年、2年生存率分彆為46.6%和27.6%,42.8%和25%,44%和26%,22.7%和9.1%, DP組、NP組之間1年、2年生存率差異無統計學意義(χ2=0.157、0.108,P>0.05),DP組、GP組之間1年、2年生存率差異無統計學意義,(χ2=0.071、0.219, P>0.05);NP組、GP組之間1年、2年生存率差異沒有統計學意義(χ2=0.014、0.022,P>0.05);DP組、NP組、GP組的1年、2年生存率均明顯高于EP 組,差異具有統計學意義(χ2=6.143、4.493、4.717和4.643、4.225、4.517,均P<0.05);(3)DP組、NP組、GP組、EP組白細胞減少、血小闆減少、貧血、神經毒性、噁心嘔吐、肝功能損害、腎功能損害的髮生率差異無統計學意義(均P>0.05)。結論 DP、NP、GP治療中晚期非小細胞肺癌臨床療效確切,有效率、生存率相近,且患者能耐受性均較好,均可作為一線治療方案,應根據患者特點,箇體化選擇三箇化療方案。
목적비교DP、NP、GP、EP화료방안치료비소세포폐암적림상료효여안전성차이,위비소세포폐암방안적우화제공차감。방법회고분석208례부합입조표준적만기비소세포폐암환자적림상자료,안수궤추사적원칙분위4조,분별위DP조58례、NP조56례、GP조50례、EP조44례,DP조급여다서타새+순박치료,NP조급여장춘서빈+순박치료,GP조급여길서타빈+순박치료,EP조급여의탁박감+순박치료,비교불동치료방안적WHO실체류근기료효,기록시험과정출현적불량반응진행비교,분석생존정황。결과(1)DP조、NP조、GP조、EP조적총유효솔분별위56%、54%、48%、36%,DP조、NP조지간총유효솔차이무통계학의의(χ2=1.103, P>0.05), DP조、GP조지간총유효솔차이무통계학의의(χ2=1.162, P>0.05),NP조、GP조지간총유효솔차이무통계학의의(χ2=0.142,P>0.05),DP조、NP조、GP조균명현고우EP조,차이구유통계학의의(χ2=25.184、19.636、19.821,균P<0.05);(2) DP조、NP조、GP조、EP조1년、2년생존솔분별위46.6%화27.6%,42.8%화25%,44%화26%,22.7%화9.1%, DP조、NP조지간1년、2년생존솔차이무통계학의의(χ2=0.157、0.108,P>0.05),DP조、GP조지간1년、2년생존솔차이무통계학의의,(χ2=0.071、0.219, P>0.05);NP조、GP조지간1년、2년생존솔차이몰유통계학의의(χ2=0.014、0.022,P>0.05);DP조、NP조、GP조적1년、2년생존솔균명현고우EP 조,차이구유통계학의의(χ2=6.143、4.493、4.717화4.643、4.225、4.517,균P<0.05);(3)DP조、NP조、GP조、EP조백세포감소、혈소판감소、빈혈、신경독성、악심구토、간공능손해、신공능손해적발생솔차이무통계학의의(균P>0.05)。결론 DP、NP、GP치료중만기비소세포폐암림상료효학절,유효솔、생존솔상근,차환자능내수성균교호,균가작위일선치료방안,응근거환자특점,개체화선택삼개화료방안。
Objective To compare the clinical efficacy and safety of DP ,NP,GP,EP chemotherapy in the treatment of non-small cell lung cancer ,to provide a reference for optimizating non-small cell lung cancer program . Methods Make a retrospective analysis of 208 non-small cell lung cancer patients data met the inclusion criteria of advanced non-small cell lung cancer , were divided into four groups according to the random number table , respectively,DP(n=58),NP(n=56),GP(n=50),EP(n=40),DP group was given docetaxel and cisplatin ,NP group was given vinorelbine and cisplatin ,GP group was given gemcitabine gemcitabine and cisplatin ,EP group was given etoposide and cisplatin , compared the WHO solid tumor efficacy of different treatment , recorded adverse reactions during the experiment , made a analysis of survival .Results ( 1 ) The total efficiency of DP group , NP group,GP group,EP group were respectively 56%,54%,48%,36%,there were no difference between NP groups and DP group(χ2 =1.103,P>0.05),between DP group and GP group (χ2 =1.162,P>0.05),between NP group and GP group(χ2 =0.142,P>0.05),DP group,NP group,GP group were significantly higher than EP group ,the difference was statistically significant(χ2 =25.184,19.636,19.821,all P<0.05).(2)The 1-year,2-year survival rates of DP group,NP group,GP Group,EP group were respectively 46.56% and 27.6%,42.8% and 25%,44%and 22%,22.7%and 9.1%, there were no difference between DP group and NP group (χ2 =0.157 ,0.108 , P>0.05),between DP group and GP group (χ2 =0.071,0.219,P>0.05),between DP group and NP group (χ2 =0.157,0.108,P>0.05),between the DP group and GP group (χ2 =0.071,0.219,P>0.05),between NP group and GP group(χ2 =0.014,0.022,P >0.05),DP group,NP group,GP group were significantly higher than EP group,the difference were statistically significant (χ2 =6.143,4.493,4.717 and 4.643,4.225,4.517,all P <0.05);(3)There were no significant difference between DP group ,NP Group,GP Group,EP group in the incidence of leukopenia,thrombocytopenia,anemia,neurotoxicity,nausea,vomiting,liver damage,kidney dysfunction,all P >0.05.Conclusions DP,NP,GP have exact efficient in the treatment of advanced non-small cell lung cancer,have similar efficiency and survival rate ,and the patients can tolerate ,can be used as first-line therapy,should select three chemotherapy according to patient characteristics .